Ozmosi | Atazanavir Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Atazanavir

Alternative Names: atazanavir, reyataz, bms-232632, evotaz
Clinical Status: Inactive
Latest Update: 2025-11-04
Latest Update Note: News Article

Product Description

Atazanavir is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children who are at least 3 months of age and weigh at least 22 lb (10 kg). Atazanavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Although atazanavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a603019.html)

Mechanisms of Action: HIV Protease Inhibitor, Protease Inhibitor, UGT1A1 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Atazanavir

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Healthy Volunteers

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12619001607167p

2006-7041-83/hah

P1

Not yet recruiting

Healthy Volunteers

None